Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 442-466

  Zhao, Huiping ^a,b   Garg, Gaurav ^a,b   Zhao, Jinbo ^a,b   Moroni, Elisabetta ^c   Girgis, Antwan ^a,b   Franco, Lucas S ^a,b   Singh, Swapnil ^a,b   Colombo, Giorgio ^c   Blagg, Brian S J ^a,b  

^a Department of Medicinal Chemistry ^*  (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c CNR   (Italy)

Author keywords

Biphenyl; Breast cancer; Heat shock protein 90; Hsp90 C Terminal inhibitors; Structur activity relationship

Indexed keywords

2 (3 METHYLBUT 2 EN 1 YL) 4 [[3' [(1 METHYLPIPERIDIN 4 YL) OXY] [1,1' BIPHENYL] 3 YL]CARBAMOYL]PHENYL ACETATE; 2 (3 METHYLBUT 2 EN 1 YL) 4 [[4' [(1 METHYLPIPERIDIN 4 YL) OXY] [1,1' BIPHENYL] 3 YL]CARBAMOYL]PHENYL ACETATE; 2 (3 METHYLBUT 2 EN 1 YL) 4 [[4' [(1 METHYLPIPERIDIN 4 YL) OXY] [1,1' BIPHENYL] 4 YL]CARBAMOYL]PHENYL ACETATE; 2 CHLORO 4' NITRO [1,1' BIPHENYL] 4 OL; 2 METHYL 4' NITRO [1,1' BIPHENYL] 4 OL; 2 [(1 METHYLPIPERIDIN 4 YL)OXY] 5 (4 NITROPHENYL)PYRIDINE; 2' METHOXY 5' [[4' [(1 METHYLPIPERIDIN 4 YL)OXY][1,1 BIPHENYL] 4 YL]CARBAMOYL] [1,1 BIPHENYL]4 YL ACETATE; 3 CHLORO 4' NITRO [1,1' BIPHENYL] 4 OL; 3 METHOXY 4' NITRO [1,1' BIPHENYL] 4 OL; 3' CHLORO 6 METHOXY N [4' [(1 METHYLPIPERIDIN 4 YL)OXY][1,1 BIPHENYL] 4 YL] [1,1 BIPHENYL] 3 CARBOXAMIDE; 3' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 3 AMINE; 3',6 DIMETHOXY N [3' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 3 YL] [1,1' BIPHENYL] 3 YL] [1,1' BIPHENYL] 3 CARBOXAMIDE; 3',6 DIMETHOXY N [4' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 3 YL] [1,1' BIPHENYL] 3 YL] [1,1' BIPHENYL] 3 CARBOXAMIDE; 4 (3 IODOPHENOXY) 1 METHYLPIPERIDINE; 4 (4 IODOPHENOXY) 1 METHYLPIPERIDINE; 4 HYDROXY 3 (3 METHYLBUT 2 EN 1 YL) N [3' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 3 YL]BENZAMIDE; 4 HYDROXY 3 (3 METHYLBUT 2 EN 1 YL) N [4' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 3 YL]BENZAMIDE; 4 HYDROXY 3 (3 METHYLBUT 2 EN 1 YL) N [4' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 4 YL]BENZAMIDE; 4' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 3 AMINE; 4' [(1 METHYLPIPERIDIN 4 YL)OXY] [1,1' BIPHENYL] 4 AMINE; 5 BROMO 2 [(1 METHYLPIPERIDIN 4 YL)OXY]PYRIDINE; 5 [(1 METHYLPIPERIDIN 4 YL)OXY] 2 (4 NITROPHENYL)PYRIDINE; 6 (4 NITROPHENYL)PYRIDIN 3 OL; 6 METHOXY N [4' [(1 METHYLPIPERIDIN 4 YL)OXY][1,1 BIPHENYL] 4 YL] [1,1' BIPHENYL] 3 CARBOXAMIDE; AMIDE; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; BENZAMIDE DERIVATIVE; HEAT SHOCK PROTEIN 90;

ACYLATION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; ETHERIFICATION; HYDROGEN BOND; HYDROLYSIS; IC50; MCF 7 CELL LINE; PROTEIN DEGRADATION; PROTEIN FOLDING; SOLVOLYSIS; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; MOLECULAR DOCKING; SYNTHESIS;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BINDING SITES; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MCF-7 CELLS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84908431322     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.034     Document Type: Article

References (34)

1. B.S.J. Blagg, T.A. Kerr, Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation, Med. Res. Rev. 26 (2006) 310-338.
2. R. Garcia-Carbonero, A. Carnero, L. Paz-Ares, Inhibition of HSP90 molecular chaperones: moving into the clinic, Lancet Oncol. 14 (2013) e358ee369.
3. D. Picard, http://www.picard.ch/downloads/Hsp90interactors.pdf.
4. D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (2011) 646-674.
5. J.J. Barrott, T.A.J. Haystead, Hsp90, an unlikely ally in the war on cancer, FEBS J. 280 (2013) 1381-1396.
6. H. Zhao, L. Michaelis Mary, S.J. Blagg Brian, Hsp90 modulation for the treatment of Alzheimer's disease, Adv. Pharmacol. 64 (2012) 1-25.
7. Y. Miyata, H. Nakamoto, L. Neckers, The therapeutic target Hsp90 and cancer hallmarks, Curr. Pharm. Des. 19 (2013) 347-365.
8. W.J. Luo, A. Rodina, G. Chiosis, Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? Bmc Neurosci. 9 (2008).
9. L. Whitesell, S. Santagata, N.U. Lin, Inhibiting HSP90 to treat cancer: a strategy in evolution, Curr. Mol. Med. 12 (2012) 1108-1124.
10. M.G. Marcu, T.W. Schulte, L. Neckers, Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins, J. Natl. Cancer Inst. 92 (2000) 242-248.
11. M.G. Marcu, A. Chadli, I. Bouhouche, M. Catelli, L.M. Neckers, The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone, J. Biol. Chem. 275 (2000) 37181-37186.
12. S.N. Shelton, M.E. Shawgo, S.B. Matthews, Y. Lu, A.C. Donnelly, K. Szabla, M. Tanol, G.A. Vielhauer, R.A. Rajewski, R.L. Matts, B.S.J. Blagg, J.D. Robertson, KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells, Mol. Pharmacol. 76 (2009) 1314-1322.
13. J.D. Eskew, T. Sadikot, P. Morales, A. Duren, I. Dunwiddie, M. Swink, X.Y. Zhang, S. Hembruff, A. Donnelly, R.A. Rajewski, B.S.J. Blagg, J.R. Manjarrez, R.L. Matts, J.M. Holzbeierlein, G.A. Vielhauer, Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells, Bmc Cancer 11 (2011).
14. X.M. Yu, G. Shen, L. Neckers, H. Blake, J. Holzbeierlein, B. Cronk, B.S.J. Blagg, Hsp90 inhibitors identified from a library of novobiocin analogues, J. Am. Chem. Soc. 127 (2005) 12778-12779.
15. H. Kimura, H. Yukitake, Y. Tajima, H. Suzuki, T. Chikatsu, S. Morimoto, Y. Funabashi, H. Omae, T. Ito, Y. Yoneda, M. Takizawa, ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation, Chem. Biol. 17 (2010) 18-27.
16. Z.Y. Yin, E.C. Henry, T.A. Gasiewicz, (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor, Biochemistry 48 (2009) 336-345.
17. H. Zhao, B.S.J. Blagg, Inhibitors of the Hsp90 C-terminus, Inhibitors of Molecular Chaperones as Therapeutic Agents, RSC Publishing, London, 2014, pp. 259-411.
18. J.A. Burlison, L. Neckers, A.B. Smith, A. Maxwell, B.S.J. Blagg, Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90, J. Am. Chem. Soc. 128 (2006) 15529-15536.
19. A.C. Donnelly, J.R. Mays, J.A. Burlison, J.T. Nelson, G. Vielhauer, J. Holzbeierlein, B.S.J. Blagg, The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity, J. Org. Chem. 73 (2008) 8901-8920.
20. H.Z. Alison C. Donnelly, Bhaskar Reddy Kusuma, Brian S.J. Blagg, Cytotoxic sugar analogues of an optimized novobiocin scaffold, Med. Chem. Commun. 1 (2010) 165-170.
21. B.R.K. Huiping Zhao, Brian S.J. Blagg, Synthesis and evaluation of noviose replacements on novobiocin that manifest antiproliferative activity, ACS Med. Chem. Lett. 1 (2010) 311-315.
22. H. Zhao, A.C. Donnelly, B.R. Kusuma, G.E.L. Brandt, D. Brown, R.A. Rajewski, G. Vielhauer, J. Holzbeierlein, M.S. Cohen, B.S.J. Blagg, Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce antiproliferative agents, J. Med. Chem. 54 (2011) 3839-3853.
23. J.A. Burlison, C. Avila, G. Vielhauer, D.J. Lubbers, J. Holzbeierlein, B.S.J. Blagg, Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines, J. Org. Chem. 73 (2008) 2130-2137.
24. H. Zhao, E. Moroni, B. Yan, G. Colombo, B.S.J. Blagg, 3D-QSAR-assisted design, synthesis, and evaluation of novobiocin analogues, ACS Med. Chem. Lett. 4 (2013) 57-62.
25. E. Moroni, H. Zhao, B.S.J. Blagg, G. Colombo, Exploiting conformational dynamics in drug discovery: design of c-terminal inhibitors of Hsp90 with improved activities, J. Chem. Inf. Model. 54 (2014) 195-208.
26. B.R. Kusuma, A. Khandelwal, W. Gu, D. Brown, W. Liu, G. Vielhauer, J. Holzbeierlein, B.S.J. Blagg, Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors, Bio. Med. Chem. 22 (2014) 1441-1449.
27. H. Zhao, E. Moroni, B. Yan, G. Colombo, B.S. Blagg, 3D-QSAR-assisted design, synthesis, and evaluation of novobiocin analogues, ACS Med. Chem. Lett. 4 (2012) 57-62.
28. L. Costantino, D. Barlocco, Privileged structures as leads in medicinal chemistry, Curr. Med. Chem. 13 (2006) 65-85.
29. R.L. Matts, A. Dixit, L.B. Peterson, L. Sun, S. Voruganti, P. Kalyanaraman, S.D. Hartson, G.M. Verkhivker, B.S.J. Blagg, Elucidation of the Hsp90 C-terminal inhibitor binding site, Acs Chem. Biol. 6 (2011) 800-807.
30. G. Morra, M.A.C. Neves, C.J. Plescia, S. Tsustsumi, L. Neckers, G. Verkhivker, D.C. Altieri, G. Colombo, Dynamics-based discovery of allosteric inhibitors: selection of new ligands for the c-terminal domain of Hsp90, J. Chem. Theory Comput. 6 (2010) 2978-2989.
31. H. Zhao, E. Moroni, G. Colombo, B.S.J. Blagg, Identification of a new scaffold for Hsp90 C-terminal inhibition, ACS Med. Chem. Lett. 5 (2014) 84-88.
32. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, D.T. Mainz, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes, J. Med. Chem. 49 (2006) 6177-6196.
33. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, P.S. Shenkin, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking Accuracy, J. Med. Chem. 47 (2004) 1739-1749.
34. W.L. Jorgensen, D.S. Maxwell, J. Tirado-Rives, Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc. 118 (1996) 11225-11236.